NEW YORK, NY / ACCESSWIRE / September 18, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
GTT Communications, Inc. (GTT)
Class Period: February 26, 2018 - July 1, 2019
Deadline: September 30, 2019
For more info:www.bgandg.com/gtt
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) there were delays in migrating Interoute Communications Holdings S.A.’s (“Interoute”) legacy systems and processes into GTT’s client management database system; (2) Interoute had made a strategic priority shift to sell cloud services that was a higher percentage of Interoute’s sales in the two years leading up to the acquisition; (3) a material percentage of the Interoute sales representatives were not productive at selling GTT’s core cloud networking services; (4) GTT was unable to yield as many Interoute salespeople because Interoute had hired many sales people focused on cloud services and allowed underperforming sales representatives to remain at Interoute; and (5) as a result, GTT’s public statements were materially false and misleading at all relevant times.
Sarepta Therapeutics, Inc. (SRPT)
Class Period: September 6, 2017 - August 19, 2019
Deadline: October 29, 2019
For more info:www.bgandg.com/srpt
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) golodirsen posed significant safety risks to patients; (2) consequently, the NDA package for golodirsen’s accelerated approval was unlikely to receive FDA approval; and (3) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.
Aclaris Therapeutics, Inc. (ACRS)
Class Period: May 8, 2018 - June 20, 2019
Deadline: October 30, 2019
For more info:www.bgandg.com/acrs
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:(1) the Company’s advertising materials minimized the risks and overstated the efficacy of ESKATA to generate sales; (2) as a result, the Company was reasonably likely to face regulatory scrutiny; and (3) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View source version on accesswire.com: